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HIGHLIGHTS 
 The basis of designing an epitope-based vaccine against severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). 
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The outbreak of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), 
has spread worldwide and as a result, the World Health Organization 
(WHO) declared it a pandemic. At present, there are no approved 
vaccines against SARS-CoV-2. Therefore, the aim of this study was to 
predict epitope-based vaccines using bioinformatics approaches and 
phylogenetic tree construction of SARS-CoV-2 against the backdrop of 
the COVID-19 pandemic. In this study, we employed 27 isolates of 
SARS-CoV-2 spike glycoprotein genes retrieved from GenBank® 
(National Center for Biotechnology Information, USA) and the GISAID 
EpiCoV™ Database (Germany). We analyzed the candidate epitopes 
using the Immune Epitope Database and Analysis Resource. 
Furthermore, we performed protective antigen prediction with VaxiJen 
2.0. Data for B-cell epitope prediction, protective antigen prediction, and 
the underlying phylogenetic tree of SARS-CoV-2 were obtained in this 
research. Therefore, these data could be used to design an epitope-
based vaccine against SARS-CoV-2. However, advanced study is 
recommended for confirmation (in vitro and in vivo). 
This is an open-access article under the CC–BY-SA license.   
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1. INTRODUCTION 
On 30 December 2019, the Chinese government reported an outbreak of pneumonia 
disease in Wuhan.1 Furthermore, the causative agent identified by the International 
Committee on Taxonomy of Viruses (ICTV) was named SARS-CoV-2.2 This new virus has 
rapidly spread across China and other countries.3,4,5 In addition, the WHO announced a new 
name for the disease caused by SARS-CoV-2 coronavirus disease 2019 (COVID-19).6 At 
present, there are three coronaviruses that cause disease in humans: severe acute respiratory 
syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-
CoV), and SARS-CoV-2.7 
Coronaviruses belong to the Coronaviridae family of the order Nidovirales. The 
coronavirus family consists of alpha, beta, gamma, and delta coronaviruses. The term 
“corona” reflects the crown-like spikes on the surface of the virus. They are roughly 65–125 
nm in diameter with a single-stranded RNA of approximately 26–32 kbs in length. The 
structural proteins are encoded by four structural genes, including the envelope (E), 
membrane (M), nucleocapsid (N), and spike (S) genes; orf1ab is the largest gene in SARS-
CoV-2.8 Interestingly, the spike glycoprotein plays an important role in binding to the receptors 
of the host cell and is the major target for neutralizing antibodies.7,9 
Vaccines have been demonstrated to decrease the morbidity and mortality levels of 
many infectious diseases.10 Therefore, the development of an effective vaccine against SARS-
CoV-2 infection is urgently required. Progress in molecular biology and biotechnology is 
driving the construction of novel concepts in vaccinology. Synthetic recombinant proteins 
containing epitopes could be produced efficiently with modern biotechnology methods.11 
Hence, an epitope-based vaccine is suggested as a novel possibility for effective vaccines 
against SARS-CoV-2. In this study, we applied bioinformatics analysis to obtain data for B-
cell epitope prediction, protective antigen prediction, and molecular phylogenetic tree 
construction of SARS-CoV-2 isolates. 
 
2. MATERIALS AND METHOD 
2.1 SARS-CoV-2 isolates 
The isolates of SARS-CoV-2 were retrieved from GenBank® (National Center of Biotechnology 
Information, USA) and the GISAID EpiCoV™ Database (Table 1). 
 
Table 1. SARS-CoV-2 isolates retrieved from GenBank®. 
Accession ID Origin Host Isolation Source Database 
MT240479.1 Pakistan: Gilgit Homo sapiens Throat swab GenBank® 
MT188341.1 
USA: Minnesota 
(MN) 
Homo sapiens 
Nasopharyngeal or 
oropharyngeal swab 
GenBank® 
MN908947.3 China: Wuhan Homo sapiens Unknown GenBank® 
LC529905.1 Japan Homo sapiens Unknown GenBank® 
MT039890.1 South Korea Homo sapiens Unknown GenBank® 
MT066156.1 Italy Homo sapiens Sputum GenBank® 
MT072688.1 Nepal Homo sapiens Oropharyngeal swab GenBank® 
MN985325.1 
USA: Washington 
(WA) 
Homo sapiens Oropharyngeal swab GenBank® 
MN988713.1 USA: Illinois (IL) Homo sapiens Sputum GenBank® 
MT253701.1 
China: Zhejiang, 
Hangzhou 
Homo sapiens Sputum GenBank® 
MT007544.1 Australia: Victoria Homo sapiens Unknown GenBank® 
MT192759.1 Taiwan Homo sapiens Sputum GenBank® 
MT039888.1 
USA: Massachusetts 
(MA) 
Homo sapiens Oropharyngeal swab GenBank® 
MT106054.1 USA: Texas (TX) Homo sapiens Sputum GenBank® 
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Accession ID Origin Host Isolation Source Database 
MT233519.1 Spain: Valencia Homo sapiens 
Nasopharyngeal 
exudate 
GenBank® 
MT126808.1 Brazil Homo sapiens 
Nasopharyngeal 
swab 
GenBank® 
MN938384.1 China: Shenzhen Homo sapiens 
Nasopharyngeal 
swab 
GenBank® 
MT012098.1 India: Kerala State Homo sapiens Throat swab GenBank® 
MT093571.1 Sweden Homo sapiens Unknown GenBank® 
MT135041.1 China: Beijing Homo sapiens Unknown GenBank® 
MT121215.1 China: Shanghai Homo sapiens Throat swab GenBank® 
EPI_ISL_435281 Indonesia: Jakarta Homo sapiens 
Nasopharyngeal and 
Oro-pharyngeal 
swab 
GISAID 
EpiCoV™ 
EPI_ISL_435282 Indonesia: Jakarta Homo sapiens 
Nasopharyngeal and 
Oro-pharyngeal 
swab 
GISAID 
EpiCoV™ 
EPI_ISL_435283 Indonesia: Jakarta Homo sapiens 
Nasopharyngeal 
swab 
GISAID 
EpiCoV™ 
 
2.2 Nucleotide sequence preparation 
SARS-CoV-2 nucleotide sequences (spike glycoprotein gene) from all isolates were retrieved 
from GenBank® and the GISAID EpiCoV™ Database. Multiple sequence alignment of 
nucleotide sequences was performed using Molecular Evolutionary Genetics Analysis X 
(MEGA X).10 
2.3 Prediction of B-cell epitopes and protective antigens   
A B-cell epitope, which is known as a B-cell antigenic determinant, is a specific antigen region 
with high affinity for B-cell lymphocytes. This interaction induces B-cells to produce an antigen-
specific antibody and memory cells.12 To predict the B-cell epitope, analysis was conducted 
using the IEDB online webserver with default thresholds (0.350) and VaxiJen v2.0.10  
2.4 Molecular phylogenetic analysis 
Phylogenetic modeling and tree visualization were achieved by applying MEGA X with the 
Maximum Likelihood method.10 The phylogenetic tree was validated by running the analysis 
on 1000 bootstrapped input datasets13 and cross-referencing it against the Tamura-Nei 
substitution model.14 
 
3. RESULTS AND DISCUSSION 
A novel coronavirus, SARS-CoV-2, spread across the world very rapidly. Human-to-
human transmission has been confirmed, and the number of global cases has been increasing 
at a fast pace.9 To date, there are more than 2 million people infected with SARS-CoV-2 
worldwide based on the online interactive dashboard hosted by the Center for Systems 
Science and Engineering (CSSE) at Johns Hopkins University. This interactive web-based 
dashboard visualizes and tracks reported cases of COVID-19 in real time.15 
In addition, the spike glycoprotein has recently been regarded as a highly expectant 
antigen formulation for the construction of a SARS-CoV-2 vaccine. There are two reasons for 
this: (1) it is involved in surface exposure, directly recognized by the host immune system, and 
(2) it mediates the interaction with the host cells by binding to the receptor, ACE2.16 Muthumani 
et al. reported that a DNA vaccine encoding MERS-CoV spike glycoprotein was immunogenic 
in rhesus macaques, camels, and mice.17 Moreover, Pallesen et al. demonstrated a higher 
titer of neutralizing antibodies in mice immunized by the recombinant prefusion, MERS-CoV 
spike glycoprotein.18 In addition, Zhang et al. described various types of SARS-CoV-2 
vaccines based on a number of different developmental processes, such as whole-cell killed 
and live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccines, live vector 
vaccines, and synthetic peptides.16 
Epitopes from all samples of SARS-CoV-2 isolates were predicted using the IEDB online 
webserver to determine the potential for B-cell recognition with an accuracy of approximately 
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75%. This prediction was based on the combination of Hidden Markov Model (HMM) statistical 
methods and trend scale.10 Furthermore, the peptides were predicted using VaxiJen v2.0 to 
determine the characteristics of immunogenicity or protective antigens. Therefore, they can 
be distinguished as either non-antigens or antigens. The prediction has an accuracy of 
approximately 70-89%. The performance of this server was developed based on the 
physicochemical properties of the target protein without alignment.19  
  
Table 2. Prediction of B-cell epitopes and protective antigens of SARS-CoV-2 
Predicted Peptides Position Length Protective Antigens 
RTQLPPAYTNS 21-31 11 
0.8710 
(Probable ANTIGEN) 
SGTNGTKRFDN 71-81 11 
0.5906 
(Probable ANTIGEN) 
LTPGDSSSGWTAG 249-261 13 
0.4950 
(Probable ANTIGEN) 
VRQIAPGQTGKIAD 407-420 14 
1.2606 
(Probable ANTIGEN) 
YQAGSTPCNGV 473-483 11 
0.0881 
(Probable NON-ANTIGEN) 
YGFQPTNGVGYQ 495-506 12 
0.7136  
(Probable ANTIGEN) 
RDIADTTDAVRDPQ 567-580 14 
0.4400  
(Probable ANTIGEN) 
QTQTNSPRRARSV 675-687 13 
0.1763  
(Probable NON-ANTIGEN) 
ILPDPSKPSKRS 805-816 12 
0.5322  
(Probable ANTIGEN) 
VYDPLQPELDSF 1137-1148 12 
0.0903  
(Probable NON-ANTIGEN) 
KNHTSPDVDLG 1157-1167 11 
1.4039  
(Probable ANTIGEN) 
FDEDDSEPVL 1256-1265 10 
0.3154  
(Probable NON-ANTIGEN) 
 
 
Figure 1. Prediction of B-cell epitopes from the amino acids of spike glycoprotein of SARS-CoV-2. B-
cell epitope prediction was performed using the IEDB online webserver. The yellow region was positive, 
whereas the green region was a negative prediction of B-cell epitopes. 
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Figure 2. Phylogenetic tree of the first three SARS-CoV-2 in Indonesia and other coronaviruses. 
 
In this study, we obtained 12 predicted peptides and 8 other peptides considered as 
protective antigens (Table 2 and Figure 1). B-cell epitope prediction is a methodology to 
predict protein regions that could be recognized as an epitope response to B-cells. An epitope 
is part of an antigen molecule that binds to the antibodies. This area is essential for designing 
certain types of vaccines or specific antibodies. The design of a seed vaccine requires an 
epitope that can determine the active side of the antigen that binds to the antibodies.12 
 Recently, there have been no epitope-based vaccines seen on the market.20 However, 
over the past decade, research and development to reveal epitope-based vaccines has 
garnered much interest within the vaccine industry. Progress has been made utilizing various 
methods, such as cell culture techniques, recombinant DNA technology, and 
immunoinformatics.11 Epitope-based vaccines play an essential part in the present volume of 
research with several advantages over conventional vaccines, including robust safety and 
stability, high specificity, and better manufacturing and retention. As a result, epitope-based 
vaccines have become an increasingly popular field of vaccinology. Several studies have 
identified the potency of epitope-based antigens that efficiently generate high immunity and 
protection against various pathogens.10,12  
 Molecular phylogenetic analysis is used to address both applied and fundamental 
issues of virus research, including phylogeography, diagnostics, evolution, origin, 
epidemiology, taxonomy, and forensics. It may provide an evolutionary view of the variety of 
any character that can be measured for a cluster of viruses.21 The molecular phylogenetic 
analysis in this study exhibited the genetic relationship between SARS-CoV-2 isolates from 
various countries and other coronaviruses originating from humans, bats, and pangolins 
(Figure 2). Interestingly, we identified the newly submitted three Indonesian SARS-CoV-2 
isolates (provided by Eijkman Institute for Molecular Biology, Ministry of Research and 
Technology/National Agency for Research and Innovation of the Republic of Indonesia) from 
the GISAID EpiCoV™ Database. We revealed that there were not many differences in the 
spike glycoprotein gene between viruses isolated from various countries and those from 
Indonesia. On the other hand, Andersen et al. stated that SARS-CoV-2 is clearly not a 
laboratory construct or manipulated virus.22  
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 In addition, Lam et al. demonstrated that coronaviruses are present in many wild 
mammals in Asia.1 Currently, it is crucial to investigate the likelihood of intermediate hosts of 
SARS-CoV-2 to contain COVID-19 spread. Pangolin CoV is 91.02% identical to SARS-CoV-
2 at the whole-genome level.23 Previously, Zhou et al. stated that SARS-CoV-2 shares a 96% 
whole genome with a bat CoV from Rhinolophus affinis (BatCoV RaTG13) collected from 
Yunnan Province, China.24 Based on this study, we recommend that further surveillance 
studies be carried out on bats and pangolins in the natural environment, especially in China 
and Southeast Asia, in order to understand the risk of zoonotic transmission in the near future. 
Overall, vaccination is an effective method for controlling diseases and regulating 
human and animal health. Specifically, vaccines are agents that enhance the adaptive 
immune response and can reduce the effects of infections and diseases. This is accomplished 
through the immune system recognizing the vaccine as a foreign object, then destroying it, 
and placing it in memory. Moreover, the novel concept of reverse vaccinology has 
revolutionized the study of vaccine development. The ability to obtain a whole-genome 
sequence from a virulent organism has led to the in silico analysis of the most protective 
antigens before conducting confirmation experiments (in vitro and in vivo). Several 
advantages, such as low cost, speed, along with the success of the bioinformatics approach, 
depend on the accuracy of predictions, which are supported by many tools. 
 
4. CONCLUSION 
This study supplied data for B-cell epitope prediction, protective antigen prediction, and 
the phylogenetic tree of SARS-CoV-2. In summary, this study could serve as the basis to 
design an epitope-based vaccine against SARS-CoV-2. However, an advanced study is 
suggested for confirmation (in vitro and in vivo). 
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